The Problem
Emissions are costly. Bioactives are scarce.
- UK breweries emit 1,500–10,000 t CO₂/yr; most vent it at cost
- Carbon compliance costs rising under UK & EU emissions policy
- High-value bioactive compounds (omega-3, astaxanthin) depend on fragile supply chains
- No integrated solution captures CO₂ and generates bioactive value
The Solution
Two-arm circular economy model
- Arm 1 — Carbon Capture Service: Deploy modular containerised bioreactors on-site at breweries & industrial facilities; capture fermentation CO₂
- Arm 2 — Biomass Conversion: Feed CO₂ to proprietary microalgae strains; extract nutraceuticals, pharma IP compounds, and organic liquid fertilisers
CO₂ → Microalgae → Products → Revenue
Market Opportunity
$55B+ addressable across three markets
$17.75B
CCUS by 2030 · 25% CAGR
$1.1T
Nutraceuticals by 2035 · 7.9% CAGR
€15B
Microalgae fertilisers · EU by 2032
2,000+
UK independent breweries targeted
Revenue Model
Three recurring streams
| Stream |
Unit Economics |
Margin |
| Service Fees |
£5–15K/month per site |
70–75% |
| Nutraceuticals |
£28–55/unit DTC |
50–65% |
| IP Licensing |
£2–8M upfront + royalties |
85%+ |
Traction & IP
Validated technology, ready to deploy
4–6 microalgae strains validated
Spray-drying IP (60–70% cheaper)
Modular bioreactor design
CO₂ capture integration protocol
Bioactive profiles identified
Patent strategy in progress
Team
Dr. Robert Justin John
Founder & Chief Technology Officer
Microalgae biotechnology R&D specialist. Identified and validated proprietary strains with published bioactive profiles. Developed spray-drying extraction process and modular bioreactor architecture.
Year 1–2 hires: VP Biz Dev · Head of Operations · Bioprocess Engineer · Regulatory Affairs
Use of Funds · £2.8M–£3.5M Seed Round
Operations & buffer £650K
Year 1 milestone: 1–2 brewery pilots deployed · first extract validated · £80–120K revenue
Series A trigger (Month 18–24): 3–4 sites live · £200K+ ARR · nutraceutical launch · regulatory pathway secured
Target return: 8–15× by Year 5–7 (licensing exit or strategic acquisition)